New Massive €250M Investment Fund Closed for European Biotech

07/06/2016 - 2 minutes

Life Sciences Partners (LSP) has closed its new life sciences fund, ‘LSP5’. The fund surpassed its €152M target and reached the ‘hard cap’ of €250M, making it one of the largest life sciences funds in the EU.

lsp_lsp5_biotech_medtech_finance_europe_vc_fundLSP is one of the oldest and most successful Biotech investors in Europe. It claims over 25% return on investment per year in private investment, which is very high.

To get to this high return, it participated in many of the European success-stories, such as Qiagen, Crucell and more recently ProSensa, which went on to be sold to BioMarin for $840M in early 2015.

And it has over $1.2Bn of investment capital raised to date, managed from offices in Amsterdam, Munich and Boston. The new fund (LSP5) will invest in around 20 companies across the areas of drug development, medical devices and diagnostics.

And it has already started to invest, taking positions in 9 such companies.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member